AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: A clinicopathological study of 168 cases

Liver International

Volumn 31, Issue 6, 2011, Pages 810-816

  Schmitz, Klaus J ^a,c   Sotiropoulos, Georgios C ^a   Baba, Hideo A ^a   Schmid, Kurt W ^a   Müller, Doris ^b   Paul, Andreas ^a   Auer, Thomas ^b   Gamerith, Gabriele ^b   Loeffler Ragg, Judith ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Pathologisches Institut Recklinghausen   (Germany)

Author keywords

AKR1B10; Hepatocellular carcinoma; Histological differentiation; Immunohistochemistry; Prognosis; Stage; TNM

Indexed keywords

AKR1B10 PROTEIN; KI 67 ANTIGEN; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ALPHA 1 ANTITRYPSIN DEFICIENCY; APOPTOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE LOSS; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER SURGERY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NICK END LABELING; OVERALL SURVIVAL; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; VIRUS HEPATITIS;

EID: 79958032359     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02511.x     Document Type: Article

References (27)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
2. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
3. Lang H, Sotiropoulos GC, Brokalaki EI, et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007; 205: 27-36.
4. Sotiropoulos GC, Lang H, Frilling A, et al. Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature. Hepatogastroenterology 2006; 53: 322-9.
5. Sotiropoulos GC, Druhe N, Sgourakis G, et al. Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach? Dig Dis Sci 2009; 54: 2264-73.
6. Satow R, Shitashige M, Kanai Y, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res 2010; 16: 2518-28.
7. Heringlake S, Hofdmann M, Fiebeler A, et al. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J Hepatol 2010; 52: 220-7.
8. Teramoto R, Minagawa H, Honda M, et al. Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta 2008; 1784: 764-72.
9. Scuric Z, Stain SC, Anderson WF, Hwang JJ. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 1998; 27: 943-50.
10. Martin HJ, Maser E. Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem Biol Interact 2009; 178: 145-50.
11. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 2007; 47: 263-92.
12. Loeffler-Ragg J, Mueller D, Gamerith G, et al. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol Cancer Ther 2009; 8: 1995-2006.
13. Gallego O, Ruiz FX, Ardevol A, et al. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA 2007; 104: 20764-9.
14. Ma J, Yan R, Zu X, et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem 2008; 283: 3418-23.
15. Yoshitake H, Takahashi M, Ishikawa H, et al. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer 2007; 17: 1300-6.
16. Breton J, Gage MC, Hay AW, et al. Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma. J Proteome Res 2008; 7: 1953-62.
17. Fukumoto S, Yamauchi N, Moriguchi H, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005; 11: 1776-85.
18. Sobin LH, Wittekind C. International Union Against Cancer. TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002.
19. Schmitz KJ, Lang H, Wohlschlaeger J, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows Arch 2007; 450: 135-41.
20. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. J Clin Pathol 2009; 62: 690-3.
21. Liu Z, Zhong L, Krishack PA, et al. Structure and promoter characterization of aldo-keto reductase family 1 B10 gene. Gene 2009; 437: 39-44.
22. Ishiyama T, Kano J, Minami Y, et al. Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes. Cancer Sci 2003; 94: 757-63.
23. Ito Y, Miyoshi E, Takeda T, et al. Expression and possible role of ets-1 in hepatocellular carcinoma. Am J Clin Pathol 2000; 114: 719-25.
24. Yan R, Zu X, Ma J, et al. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int J Cancer 2007; 121: 2301-6.
25. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 3210-6.
26. Endo S, Matsunaga T, Soda M, et al. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. Biol Pharm Bull 2010; 33: 886-90.
27. Faivre S, Bouattour M, Raymond E. Novel molecular therapies in hepatocellular carcinoma. Liv Int 2011; 31 (Suppl. 1): 151-60.